RVT 3101 (previously known as PF 6480605) is a fully human immunoglobulin G1 monoclonal antibody, targeting TL1A, being developed by Roche, for the treatment of
Frank Torti, M.D, Chairman and CEO of Telavant and Vant Chair at Roivant, added: “We are eager to see RVT-3101 rapidly advance with Roche’s resources and commitment to this program. I would like to thank everyone who played a critical role in advancing the RVT-3101...